Comparative Evaluation of Recombinant Protein Production in Different Biofactories: The Green Perspective

In recent years, the production of recombinant pharmaceutical proteins in heterologous systems has increased significantly. Most applications involve complex proteins and glycoproteins that are difficult to produce, thus promoting the development and improvement of a wide range of production platforms. No individual system is optimal for the production of all recombinant proteins, so the diversity of platforms based on plants offers a significant advantage. Here, we discuss the production of four recombinant pharmaceutical proteins using different platforms, highlighting from these examples the unique advantages of plant-based systems over traditional fermenter-based expression platforms.

[1]  R. Fischer,et al.  Rapid Transient Production in Plants by Replicating and Non-Replicating Vectors Yields High Quality Functional Anti-HIV Antibody , 2010, PloS one.

[2]  E. Mylonakis,et al.  Interleukin-6 polymorphisms and hematologic malignancy: a re-appraisal of evidence from genetic association studies , 2013, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[3]  M. Sack,et al.  Plant species and organ influence the structure and subcellular localization of recombinant glycoproteins , 2013, Plant Molecular Biology.

[4]  K. Nagase,et al.  High-Level Direct Expression of Semi-Synthetic Human Interleukin-6 in Escherichia coli and Production of N-Terminus Met-Free Product , 1990, Bio/Technology.

[5]  A. Trkola,et al.  Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.

[6]  Miho Suzuki,et al.  IL-6/IL-6 receptor system and its role in physiological and pathological conditions. , 2012, Clinical science.

[7]  H. Katinger,et al.  A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1 , 2002, AIDS.

[8]  J. Nerup,et al.  Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of beta-cell function and remission in recent-onset IDDM after cyclosporin treatment. The Canadian-European Randomized Control Trial Group. , 1994, Diabetes.

[9]  A. M. Hutson,et al.  Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. , 2006, Plant biotechnology journal.

[10]  M. Estes,et al.  Recombinant Norwalk Virus-Like Particles Administered Intranasally to Mice Induce Systemic and Mucosal (Fecal and Vaginal) Immune Responses , 2001, Journal of Virology.

[11]  M. Herbst-Kralovetz,et al.  Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. , 2011, Vaccine.

[12]  John P. Moore,et al.  Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120 , 2003, Nature Medicine.

[13]  John P. Moore,et al.  Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. , 2008, Annual review of medicine.

[14]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[15]  A. Trkola,et al.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. , 1994, AIDS research and human retroviruses.

[16]  A. Xu,et al.  Large-scale production, purification and bioactivity assay of recombinant human interleukin-6 in the methylotrophic yeast Pichia pastoris. , 2011, FEMS yeast research.

[17]  J. Whisstock,et al.  GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop , 2007, Nature Structural &Molecular Biology.

[18]  R Fischer,et al.  New downstream processing strategy for the purification of monoclonal antibodies from transgenic tobacco plants. , 2008, Journal of chromatography. A.

[19]  D. Ejima,et al.  High yield refolding and purification process for recombinant human interleukin-6 expressed in Escherichia coli. , 1999, Biotechnology and bioengineering.

[20]  Kevin Barraclough,et al.  I and i , 2001, BMJ : British Medical Journal.

[21]  C. Tacket,et al.  Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. , 2003, Clinical immunology.

[22]  Norovirus vaccine development: next steps , 2012, Expert review of vaccines.

[23]  A. Depicker,et al.  Non-food/feed seeds as biofactories for the high-yield production of recombinant pharmaceuticals. , 2011, Plant biotechnology journal.

[24]  W. Marsden I and J , 2012 .

[25]  K. Musiychuk,et al.  A plant‐based system for rapid production of influenza vaccine antigens , 2011, Influenza and other respiratory viruses.

[26]  D. Montefiori,et al.  Rapid High-Level Production of Functional HIV Broadly Neutralizing Monoclonal Antibodies in Transient Plant Expression Systems , 2013, PloS one.

[27]  R. Kunert,et al.  Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. , 2007, Plant biotechnology journal.

[28]  Michael Goodman Pharmaceutical industry financial performance , 2009, Nature Reviews Drug Discovery.

[29]  A. Jevnikar,et al.  Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Levine,et al.  Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. , 2000, The Journal of infectious diseases.

[31]  H. Katinger,et al.  Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation , 2002, AIDS.

[32]  M G Rossmann,et al.  X-ray crystallographic structure of the Norwalk virus capsid. , 1999, Science.

[33]  M. Xia,et al.  Norovirus capsid protein expressed in yeast forms virus‐like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts , 2007, Journal of medical virology.

[34]  O. Dym,et al.  Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. , 2007, Plant biotechnology journal.

[35]  M. Estes,et al.  Oral Immunization with Recombinant Norwalk Virus-Like Particles Induces a Systemic and Mucosal Immune Response in Mice , 1998, Journal of Virology.

[36]  Y. Chang,et al.  Production of Soluble Human Interleukin‐6 in Cytoplasm by Fed‐Batch Culture of Recombinant E. coli , 2008, Biotechnology progress.

[37]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[38]  R. Twyman,et al.  Optimizing the yield of recombinant pharmaceutical proteins in plants. , 2013, Current pharmaceutical design.

[39]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.

[40]  I. Broer,et al.  Recombinant Production of Human Interleukin 6 in Escherichia coli , 2013, PloS one.

[41]  S. Baekkeskov,et al.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase , 1990, Nature.

[42]  E. Eddings,et al.  Large Scale Production , 2013 .

[43]  J. Nerup,et al.  Glutamic Acid Decarboxylase (GAD65) Autoantibodies in Prediction of β-Cell Function and Remission in Recent-Onset IDDM After Cyclosporin Treatment , 1994, Diabetes.

[44]  S. Morikawa,et al.  Expression of IL‐6/IFN‐B2 in a Baculovirus System and Its Biological Function , 1989, Annals of the New York Academy of Sciences.

[45]  Carole Plasson,et al.  Plant-specific glycosylation patterns in the context of therapeutic protein production. , 2010, Plant biotechnology journal.

[46]  H. Steinkellner,et al.  Generation of Arabidopsis thaliana plants with complex N‐glycans lacking β1,2‐linked xylose and core α1,3‐linked fucose , 2004 .

[47]  Yihong Yao,et al.  Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. , 2014, Pharmacology & therapeutics.

[48]  C. Madeddu,et al.  The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications—a review , 2013, Journal of Molecular Medicine.

[49]  R. Johnston,et al.  Expression and Self-Assembly of Norwalk Virus Capsid Protein from Venezuelan Equine Encephalitis Virus Replicons , 2002, Journal of Virology.

[50]  T. Hirano,et al.  Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[51]  M. Herbst-Kralovetz,et al.  Norwalk virus-like particles as vaccines , 2010, Expert review of vaccines.

[52]  Michael Engle,et al.  Robust production of virus-like particles and monoclonal antibodies with geminiviral replicon vectors in lettuce. , 2012, Plant biotechnology journal.

[53]  R. Fischer,et al.  Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. , 2008, Plant biotechnology journal.

[54]  R. Twyman,et al.  GMP issues for recombinant plant-derived pharmaceutical proteins. , 2012, Biotechnology advances.

[55]  S. Nagataki,et al.  Expression of recombinant human glutamic acid decarboxylase (GAD) in myeloma cells and enzyme-linked immunosorbent assay (ELISA) for autoantibodies to GAD. , 1997, Journal of Biochemistry (Tokyo).

[56]  N. Aoki,et al.  Binding of Norovirus Virus-Like Particles (VLPs) to Human Intestinal Caco-2 Cells and the Suppressive Effect of Pasteurized Bovine Colostrum on This VLP Binding , 2010, Bioscience, biotechnology, and biochemistry.

[57]  Manish M Patel,et al.  Systematic Literature Review of Role of Noroviruses in Sporadic Gastroenteritis , 2008, Emerging infectious diseases.

[58]  M. Pezzotti,et al.  Transgenic plants expressing human glutamic acid decarboxylase (GAD65), a major autoantigen in insulin-dependent diabetes mellitus , 1999, Molecular Breeding.

[59]  D. Graham,et al.  Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein , 1992, Journal of virology.

[60]  R. Twyman,et al.  Commercial aspects of pharmaceutical protein production in plants. , 2013, Current pharmaceutical design.

[61]  G. Jennings,et al.  Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. , 2007, Current molecular medicine.

[62]  T. Vedvick,et al.  Conformational Stability and Disassembly of Norwalk Virus-like Particles , 2006, Journal of Biological Chemistry.

[63]  D. Gottlieb,et al.  Characterization of a cDNA coding for rat glutamic acid decarboxylase. , 1990, Brain research. Molecular brain research.

[64]  R. Johnston,et al.  Systemic, Mucosal, and Heterotypic Immune Induction in Mice Inoculated with Venezuelan Equine Encephalitis Replicons Expressing Norwalk Virus-Like Particles , 2002, Journal of Virology.

[65]  A. Depicker,et al.  Production of monoclonal antibodies with a controlled N-glycosylation pattern in seeds of Arabidopsis thaliana. , 2011, Plant biotechnology journal.

[66]  I. Broer,et al.  High-Level Transient Expression of ER-Targeted Human Interleukin 6 in Nicotiana benthamiana , 2012, PloS one.

[67]  C Russell Middaugh,et al.  Physical stabilization of Norwalk virus-like particles. , 2008, Journal of pharmaceutical sciences.

[68]  Bente Klarlund Pedersen,et al.  The anti-inflammatory effect of exercise. , 2005, Journal of applied physiology.

[69]  R. Roca,et al.  Engineering photoassimilate partitioning in tobacco plants improves growth and productivity and provides pathogen resistance. , 2003, The Plant journal : for cell and molecular biology.

[70]  B. Rees Smith,et al.  Glutamic acid decarboxylase autoantibody assay using 125I-labelled recombinant GAD65 produced in yeast. , 1996, Clinica chimica acta; international journal of clinical chemistry.

[71]  J. Mascola Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. , 2002, Vaccine.

[72]  M. Papouchado,et al.  Highly-sensitive and specific enzyme-linked immunosorbent assays for GAD65 autoantibodies using a thioredoxin-GAD65 fusion antigen. , 1997, Journal of immunological methods.

[73]  H. Katinger,et al.  Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. , 1998, AIDS research and human retroviruses.

[74]  Å. Lernmark,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Recognition of Glutamic Acid Decarboxylase (GAD) by Autoantibodies from Different GAD Antibody-Positive Phenotypes* , 2000 .

[75]  Xiaofeng Wang,et al.  A novel expression platform for the production of diabetes-associated autoantigen human glutamic acid decarboxylase (hGAD65) , 2008, BMC biotechnology.

[76]  E. Pedrazzini,et al.  Recombinant human GAD65 accumulates to high levels in transgenic tobacco plants when expressed as an enzymatically inactive mutant. , 2010, Plant biotechnology journal.

[77]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Alzheimer's Disease , 2010, Biological Psychiatry.

[78]  J. Barbero,et al.  Production and secretion of human interleukin 6 into the periplasm of Escherichia coli: efficient processing of N-terminal variants of hIL6 by the E. coli signal peptidase. , 1993, Journal of biotechnology.

[79]  R. Fischer,et al.  Optimal nitrogen supply as a key to increased and sustained production of a monoclonal full‐size antibody in BY‐2 suspension culture , 2010, Biotechnology and bioengineering.

[80]  J. Scheller,et al.  Influence of elastin-like peptide fusions on the quantity and quality of a tobacco-derived human immunodeficiency virus-neutralizing antibody. , 2009, Plant biotechnology journal.

[81]  V. Pantaleo Plant RNA silencing in viral defence. , 2011, Advances in experimental medicine and biology.

[82]  R. Twyman,et al.  Target product selection - where can Molecular Pharming make the difference? , 2013, Current pharmaceutical design.

[83]  C. Hong,et al.  Expression of Active Human Interleukin-6 in Transgenic Tobacco , 1995, Molecules and Cells.

[84]  D. Ghiringhelli,et al.  Expression of properly folded human glutamate decarboxylase 65 as a fusion protein in Escherichia coli. , 1997, European journal of biochemistry.

[85]  S. Amar,et al.  Atheroprotective role of interleukin-6 in diet- and/or pathogen-associated atherosclerosis using an ApoE heterozygote murine model. , 2008, Atherosclerosis.

[86]  M. Febbraio,et al.  Contraction-Induced Myokine Production and Release: Is Skeletal Muscle an Endocrine Organ? , 2005, Exercise and sport sciences reviews.

[87]  B. Hjelm,et al.  A DNA replicon system for rapid high‐level production of virus‐like particles in plants , 2009, Biotechnology and bioengineering.

[88]  J. Smolen,et al.  Interleukin-6: a new therapeutic target , 2006, Arthritis research & therapy.

[89]  A. Moody,et al.  Isolation by anion-exchange of immunologically and enzymatically active human islet glutamic acid decarboxylase 65 overexpressed in Sf9 insect cells , 2006, Diabetologia.

[90]  F. Balkwill Re: Possible Role of Ovarian Epithelial Inflammation in Ovarian Cancer. , 2000, Journal of the National Cancer Institute.

[91]  G. Stiegler,et al.  Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. , 2008, Plant biotechnology journal.

[92]  D. Graham,et al.  Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. , 1999, Gastroenterology.

[93]  S. Baekkeskov,et al.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase , 1990, Nature.

[94]  S. Matsuura,et al.  Characterization of Monoclonal Antibodies Generated against Norwalk virus Gil Capsid Protein Expressed in Escherichia coli , 2000, Microbiology and immunology.

[95]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[96]  P. Christou,et al.  Cost-effective production of a vaginal protein microbicide to prevent HIV transmission , 2008, Proceedings of the National Academy of Sciences.

[97]  S. El-Kamary,et al.  Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. , 2010, The Journal of infectious diseases.

[98]  Mackay,et al.  Comparative expression and purification of human glutamic acid decarboxylase from Saccharomyces cerevisiae and Pichia pastoris. , 2000, Enzyme and microbial technology.

[99]  H. Daniell,et al.  Plant-made vaccine antigens and biopharmaceuticals , 2009, Trends in Plant Science.

[100]  M. Estes,et al.  Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[101]  N. Nishimoto,et al.  Interleukin‐6 as a Therapeutic Target in Candidate Inflammatory Diseases , 2010, Clinical pharmacology and therapeutics.

[102]  Qiang Chen,et al.  Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations , 2011, Plant Cell Reports.

[103]  J. Ali,et al.  Oral delivery of therapeutic proteins and peptides: a review on recent developments , 2013, Drug delivery.

[104]  T. Hirano,et al.  Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[105]  A. Trkola,et al.  Long-Term Multiple-Dose Pharmacokinetics of Human Monoclonal Antibodies (MAbs) against Human Immunodeficiency Virus Type 1 Envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5) , 2006, Antimicrobial Agents and Chemotherapy.

[106]  R. Twyman,et al.  Transgenic plants in the biopharmaceutical market , 2005, Expert opinion on emerging drugs.

[107]  Ashutosh Chilkoti,et al.  Purification of recombinant proteins by fusion with thermally-responsive polypeptides , 1999, Nature Biotechnology.

[108]  M. Miyazaki,et al.  Purification of L-Glutamate Decarboxylase from Monkey Brain , 2008, Bioscience, biotechnology, and biochemistry.

[109]  B. V. von Specht,et al.  Cloning and hemolysin-mediated secretory expression of a codon-optimized synthetic human interleukin-6 gene in Escherichia coli. , 2002, Protein expression and purification.

[110]  A. Tobin,et al.  Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes , 1993, Nature.

[111]  T. Hirano,et al.  High-level expression of human BSF-2/IL-6 cDNA in Escherichia coli using a new type of expression-preparation system. , 1988, Journal of biochemistry.

[112]  C. C. Hsu,et al.  A novel method for expression and large-scale production of human brain l-glutamate decarboxylase. , 2000, Biochemical and biophysical research communications.

[113]  S. Marillonnet,et al.  Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[114]  Mario Pezzotti,et al.  Comparative analysis of different biofactories for the production of a major diabetes autoantigen , 2013, Transgenic Research.

[115]  Craig W. Hedberg,et al.  Foodborne Illness Acquired in the United States , 2011, Emerging infectious diseases.

[116]  W. Scherbaum,et al.  Baculovirus-mediated expression of human 65 kDa and 67 kDa glutamic acid decarboxylases in SF9 insect cells and their relevance in diagnosis of insulin-dependent diabetes mellitus. , 1993, Journal of biochemistry.

[117]  R. Levy,et al.  Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. , 2003, Journal of immunological methods.

[118]  M. Pezzotti,et al.  Improved in Planta Expression of the Human Islet Autoantigen Glutamic Acid Decarboxylase (GAD65) , 2003, Transgenic Research.

[119]  D. Graham,et al.  Norovirus vaccine against experimental human Norwalk Virus illness. , 2011, The New England journal of medicine.

[120]  R. Tisch,et al.  Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice , 1993, Nature.

[121]  M. Estes,et al.  Norovirus gastroenteritis. , 2009, The New England journal of medicine.

[122]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[123]  B. Hjelm,et al.  An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. , 2008, Vaccine.

[124]  Markus Lipp,et al.  Application of two-dimensional gel electrophoresis to interrogate alterations in the proteome of gentically modified crops. 3. Assessing unintended effects. , 2006, Journal of agricultural and food chemistry.

[125]  Neil Genzlinger A. and Q , 2006 .